2seventy bio Completes Merger, Delists from Nasdaq

2seventy bio ( (TSVT) ) just unveiled an update.

On May 13, 2025, 2seventy bio completed a merger that led to significant changes in its corporate structure and stock market presence. The company terminated its 2021 Employee Stock Purchase Plan and Stock Option and Incentive Plan, and requested Nasdaq to suspend trading and delist its common stock. As a result, 2seventy bio’s shares will no longer be listed on Nasdaq, and it plans to terminate its registration and reporting obligations with the SEC. Additionally, the merger resulted in a complete overhaul of the company’s board of directors and executive team, with new appointments including Sandra Ramos-Alves as President and Treasurer.

The most recent analyst rating on (TSVT) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on 2seventy bio stock, see the TSVT Stock Forecast page.

Spark’s Take on TSVT Stock

According to Spark, TipRanks’ AI Analyst, TSVT is a Neutral.

2seventy bio exhibits significant financial difficulties, with declining revenues and persistent losses overshadowing the company’s performance. Technical indicators show strong momentum, but overbought signals could limit further gains. Poor valuation metrics add to the concerns, reflecting the challenges faced by the company amid high volatility.

To see Spark’s full report on TSVT stock, click here.

More about 2seventy bio

Average Trading Volume: 1,409,216

Technical Sentiment Signal: Buy

Current Market Cap: $266.1M

For an in-depth examination of TSVT stock, go to TipRanks’ Stock Analysis page.